Background
==========

Cancer Research UK (2007) \[[@B1]\] stated that the most common cancer for women in the United Kingdom is breast cancer. In 2004, about 20% of all breast cancer cases diagnosed would lead to death \[[@B2]\]. The accepted prognostic factors fail to establish accurately the outcome for breast cancer patients as a large proportion of those diagnosed with invasive breast carcinomas are given aggressive treatments even though many of them are unlikely to develop a life-threatening cancer even without therapies. Over the past decade, many genetic and molecular pathways have been associated with breast cancer. To progress towards personalized therapies, there is a need for novel bio-markers for diagnosis, for the detection of metastasis and as targets for new selective immunotherapies. The *BUC*genes (Breast UniGene Cluster) are novel breast-associated genes identified on the basis of their specific expression spectrum, which includes testis, normal breast and breast cancer tissue. During *in silico*analysis of the *BUC*gene sequence, we discovered that the *BUC11*gene sequence shares significant similarity with the gene sequence of an unpublished gene that codes for a predicted protein (source data obtained from the NCBI website \[[@B3]\]).

Methods
=======

siRNA was designed for specific *BUC11*silencing. *BUC11*siRNA efficacy was first tested using real-time RT-PCR following transfection and mRNA isolation. The transfection of breast cancer cell line MDA231 was carried out using INTERFERin siRNA Transfection reagent (Autogen Bioclear, Calne, UK). The experiment was performed in duplicate wells. Each experiment comprised cells with *BUC11*gene-specific siRNA, cells with negative control siRNA, cells with INTERFERin alone and cells alone. On day 2, ^3^H-thymidine (Sigma-Aldrich, Gillingham, UK) was added to the cells. On day 3, cell suspensions were transferred to a filter plate, Microscint solution (Packard, Meriden, CT, USA) was added and the reading of the plate was performed. The procedure was repeated on day 7 and on day 10. To quantify gene expression at the mRNA level in breast tumours, conventional RT-PCR as well as real-time quantitative RT-PCR were carried out. Samples used in this study come from various invasive and noninvasive histological subtypes of breast cancer, different malignancies (for example, melanoma, testis cancer, mesothelioma) and normal tissues.

Results
=======

Regarding *BUC11*gene knockdown, 72 hours following transfection, 89.7% of specific inhibition of *BUC11*mRNA expression was observed (real-time RT-PCR results). Three days following transfection of MDA231 with *BUC11*siRNA, cell proliferation was inhibited by 98%. This result is still observed 7 days following transfection. However, the inhibition of proliferation is no longer observed 10 days following transfection, which is not surprising due to the transient nature of transfection. The *BUC11*gene was expressed in 90% of the breast cancer tissues tested. *BUC11*mRNA was not (or at very low levels) expressed in the normal tissues tested (heart, liver, prostate, brain, uterus, spleen, skeletal muscle, lung, kidney, placenta, trachea, thyroid, spinal cord, salivary gland, thymus and peripheral blood mononuclear cell) except for normal testis and normal breast tissues. *BUC11*mRNA was expressed in varying levels in the breast cancer samples tested. *BUC11*mRNA was expressed at similar levels in the normal testis and testicular cancer tissues tested. *BUC11*mRNA was only expressed in the breast cancer cell lines T47D and MDA231. Furthermore, *BUC11*mRNA appears to be overexpressed in breast tumour compared with the normal counterpart in the early stages of the disease and down-regulated in more advanced aggressive breast cancers. Finally, *BUC11*mRNA was not expressed in any of the other cancer samples tested (oesophageal, mesothelioma, melanoma, gastric and kidney).

Conclusion
==========

*BUC11*could potentially be a good candidate for the diagnosis and prognosis of breast cancer due to the correlation of *BUC11*gene expression with the stage of breast cancer. siRNA silencing of *BUC11*led to the inhibition of the proliferation of MDA231 breast cancer cells. This suggests that *BUC11*might have a role in the proliferation of cancer cells in the breast. The tissue specificity of the *BUC11*expression profile provides a rationale to consider *BUC11*as a tissue-specific gene involved in the differentiation of breast and testis tissues. If the restricted expression spectrum is confirmed in a larger cohort of samples, *BUC11*could be useful to detect micrometastasis in the lymph nodes or peripheral blood of breast cancer patients. Finally, *BUC11*gene is not expressed in vital organs; thus it could potentially be a good target for vaccine strategies.
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